# An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

> **NCT01458249** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 52 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** eribulin mesylate

## Key facts

- **NCT ID:** NCT01458249
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-11
- **Final completion:** 2016-02
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458249, "An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01458249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*